The executive Board of BiotechnetSwitzerland, together with Platform leaders and the Advisory board met to redefine its Strategy for 2022 and beyond.

Thank you all for your maintained committment!

Soon, we will inform of the specific outcome. For now, let's say that we are motivated and looking forward to the future

Let's biotech!!!!!!

Laura Suter-Dick

President biotechnet

Report compiled by the SBA and released on April 20th 2021

Primary and stem cells are becoming important sources for the generation of organotypic tissue models used in many biopharmaceutical applications, regenerative medicine, disease modelling and drug discovery. They promise to revolutionize the drug discovery process at all stages, from target identification through to toxicology studies.

A secure supply of food around the globe is not to be taken for granted. On the one hand the world population is growing fast, about 230’000 people per day, on the other hand climate change as well as rapidly spreading diseases block the production of food dramatically. Crop losses in the largest growing areas amount globally to 30%. Cellular agriculture focusing on the sustainable production of agriculture products from cell cultures in a laboratory instead of using livestock may provide a solution.
 

“The road to success consists in teaming up with the right partners”.

For years, researchers led by Professor Fabian Fischer at HES-SO Valais have been concentrating on microbial fuel cells, also called bio-electrochemical systems, which use electrogenic bacteria to generate electricity. Their latest innovation is a device consisting of about 14 metres of joined-up microbial fuel cells, housed in the ‘catacombs’ – a series of underground tunnels – beneath the wastewater treatment plant in Sion. It uses bio-electrogenic rather than aerobic microbes for the primary purpose of producing energy and purified water, but also to save electricity.
 

Le secteur de la santé et des sciences de la vie croît inexorablement. C’est aujourd’hui une industrie qui pèse plusieurs milliards de dollars. En 2016, les entreprises actives dans ce domaine ont affiché des ventes à hauteur de 140 milliards de dollars et leurs bénéfices ont plus que doublé par rapport à 2010. Les secteurs pharmaceutique, chimique, ainsi que ceux des technologies médicales et du dépistage, sont devenus la principale industrie d’exportation de la Suisse.